Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

11,818 recalls · Class II, newest first

Class II · Moderate risk

Ganciclovir for Injection

Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.

Terminated Labeling / mix-up Hikma Pharmaceuticals USA Inc. NDC 0143-9299-01 D-0090-2023
Class II · Moderate risk

Rifampin Capsules USP

Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.

Terminated Impurity / degradation Lupin Pharmaceuticals Inc. NDC 68180-659-06 D-0100-2023
Class II · Moderate risk

Menastil

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. NDC 66233-711-01 D-0084-2023
Class II · Moderate risk

ProSirona

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. NDC 66233-712-01 D-0083-2023
Class II · Moderate risk

Neuroquell

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. D-0082-2023
Class II · Moderate risk

Neuroquell Plus

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. D-0081-2023
Class II · Moderate risk

Quinapril Tablets USP

CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Terminated Nitrosamine impurity Lupin Pharmaceuticals Inc. NDC 68180-558-09 D-0089-2023
Class II · Moderate risk

Quinapril Tablets USP

CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Terminated Nitrosamine impurity Lupin Pharmaceuticals Inc. NDC 68180-554-09 D-0088-2023
Class II · Moderate risk

Sensorcaine-MPF

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Terminated Wrong potency / content Fresenius Kabi USA, LLC NDC 63323-468-01 D-0129-2023
Class II · Moderate risk

Sensorcaine

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Terminated Wrong potency / content Fresenius Kabi USA, LLC NDC 63323-463-01 D-0128-2023
Class II · Moderate risk

Sensorcaine

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Terminated Wrong potency / content Fresenius Kabi USA, LLC NDC 63323-461-01 D-0127-2023

Recalls by year